39,964 Shares in Palvella Therapeutics, Inc. $PVLA Bought by WCM Investment Management LLC

WCM Investment Management LLC acquired a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 39,964 shares of the company’s stock, valued at approximately $4,982,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PVLA. KBC Group NV bought a new position in Palvella Therapeutics in the 1st quarter worth about $28,000. Swiss National Bank boosted its position in shares of Palvella Therapeutics by 36.6% during the 1st quarter. Swiss National Bank now owns 19,400 shares of the company’s stock valued at $2,418,000 after acquiring an additional 5,200 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Palvella Therapeutics by 65.3% during the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after purchasing an additional 253,128 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Palvella Therapeutics by 10.9% during the first quarter. Bank of New York Mellon Corp now owns 18,041 shares of the company’s stock worth $2,249,000 after purchasing an additional 1,777 shares in the last quarter. Finally, Calamos Advisors LLC bought a new position in shares of Palvella Therapeutics in the first quarter worth approximately $1,222,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Chardan Capital reissued a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Stephens reaffirmed an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, HC Wainwright lifted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Palvella Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Palvella Therapeutics Trading Down 21.0%

Shares of NASDAQ PVLA opened at $124.15 on Tuesday. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -29.77 and a beta of -0.20. Palvella Therapeutics, Inc. has a 1-year low of $29.59 and a 1-year high of $161.38. The stock’s 50-day moving average is $125.30 and its 200 day moving average is $115.57.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, analysts forecast that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.